In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing the risk for dementia and Alzheimer's disease.

(HealthDay News) — From 2010 to 2014 there was an increase in use of diabetes medications, including sulfonylureas and dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), among patients with ...

They also examined the incidence of serious liver events. The people who used GLP-1s or SGLT-2 inhibitors had fewer cardiovascular events than those who were given DPP-4 inhibitors.